Protalix Biotherapeutics, a biopharmaceutical company focused on developing recombinant therapeutic proteins expressed through its plant cell-based expression system, is prioritizing pipeline candidates to focus on bio-better products with a clear competitive advantage. Therapeutic areas of focus will include Fabry disease, inflammatory bowel disease, ...

Rehovot-based NeuroDerm Ltd. (NASDAQ: NDRM) ended 2014 on a high note as it saw its share price more than double following announcement of positive results in a Phase IIa Parkinson’s drug trial. According to the company, administration of a continuous subcutaneous high-level dose of ...

Enzymotec Ltd., an Israel-based global company that modifies lipids harvested from natural sources to develop nutritional ingredients and medical foods, will hold an Extraordinary General Meeting of Shareholders in February. The purpose of the meeting is to elect a director, approve ...

Therapix Biosciences subsidiary OrImmune Bio has entered into a strategic collaboration with Nanjing BioSciKin Co to discuss an exclusive license to develop, manufacture and commercialize the company’s anti-CD3 antibody in China. As part of the agreement, Nanjing BioSciKin would provide a $300,000 cash ...

Pluristem Therapeutics Inc. (Nasdaq:PSTI, TASE:PSTI) announced that a study of its PLacental eXpanded (PLX) cells was accepted for publication in the February 2015 issue of Biochimica et Biophysica Acta Molecular Cell Research. The study shows that PLX cells protect various nerve cells from death after ...

Compugen (NASDAQ:CGEN; TASE:CGEN) has entered into a multi-year research collaboration with Johns Hopkins University School of Medicine to evaluate novel “immune checkpoint” candidates discovered by Compugen for potential treatment of cancer. The research will be directed by Johns Hopkins University’s Prof. Drew Pardoll ...

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has announced that the U.S. Food and Drug Administration (FDA) approved QNASL® (beclomethasone dipropionate) 40 mcg for treatment of seasonal and year-round nasal symptoms associated with allergic rhinitis (AR) in children 4-11 years of age. An ...

BioBlast Pharma (NASDAQ:ORPN) of Tel Aviv has been granted Orphan Drug status by the U.S. Food & Drug Administration (FDA) for its product candidate Cabaletta for the treatment of Spinocerebellar Ataxia Type 3 (also known as SCA3 or Machado-Joseph disease. This is the second ...

Following the trend of Israeli biotechs going public, Rehovot-based NeuroDerm has filed with the SEC to raise $65 million in an initial public offering. The company plans to list on the NASDAQ under the ticker symbol ‘NDRM’. Jefferies LLC and Cowen & ...

Employees of Teva Pharmaceutical Industries Ltd. can rest easy. According to Chief Financial Officer Eyal Desheh, there are no new plans to cut jobs in the near future. This should come as a relief after the massive 5,000 employee layoff ...